
BioBonds
For creating a new market for low-interest loans to advance more treatments and cures into clinical trials.
About BioBonds
The Long-term Opportunities for Advancing New Studies (LOANS) for Biomedical Research Act – HR 3437 – will help advance much-needed treatments and cures for a broad range of diseases and conditions into clinical trials without significantly impacting the taxpayer burden.
Unfortunately, the COVID-19 pandemic delayed or halted more than 1,000 clinical trials for treatments and cures for so many devastating conditions including cancer, eye diseases, and Alzheimer’s and Parkinson’s diseases. While the pandemic significantly slowed progress for biomedical research, the expedient development of COVID-19 vaccines showed us that financial investment can greatly accelerate the research needed to overcome these conditions.
Learn more about the LOANS Act

Loans for Biomedical Research Act
Legislation provides innovative financing for clinical trials stalled by COVID-19 pandemic.
“BioBonds: Generating Billions in Private-Sector Investment Speeding Treatment and Cure” White Paper
Authored by Karen Petrou, Member, Foundation Fighting Blindness Board of DirectorsOrganizations Supporting BioBonds





























In the News
-
July 29, 2022
Biomedical financing must not be a casualty of the current downturn
-
March 23, 2022
Few & Far Between: Conversations About Rare Disease Research featuring Karen Petrou and David Brint – BioBonds
-
November 18, 2021
A financial innovation that could cure diseases
-
October 6, 2021
COVID Revealed What Science Can Do When Funding is Found
-
July 12, 2021
BioBonds Use Wall Street Tools to Fund Medical Research
-
May 28, 2021
Jump Start Stalled Medical Research, U.S. Rep. Rush Says
-
May 24, 2021
U.S. Bond Program Proposed to Spur R&D for Unmet Medical Needs
-
May 24, 2021
JPMorgan Tries Again on Healthcare After Haven Implodes
-
May 24, 2021
Bipartisan House Bill Seeks New $30B ‘BioBonds’ Loan Program to Reinvigorate Clinical Trials
-
May 24, 2021
Lawmakers Pitch a Bill to Create $30 Billion in ‘BioBonds’ to Jumpstart Drug Development